Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Edward O'Neill

Postdoctoral Researcher


Peptide Receptor Radionuclide Therapy (PRRT) is a promising second-line treatment for patients with neuroendocrine tumours. Currently, PRRT is delivered as a one-size-fits-all dose protocol, and although offering significant improvements to patient quality of life, it largely remains a palliative treatment. In order to progress PRRT such as 177Lu-DOTATATE  into a treatment with curative intent, one strategy is to increase the injected radionuclide dose. Yet to justify any increase in radioactivity and risk additional normal toxicity, a suitable metric is needed to determine the required 177Lu dose for each tumour within a patient.

I have recently demonstrated the ability to image the DNA double strand break marker yH2AX generated in response to 177Lu-DOTATATE therapy in pre-clinical models. I am currently determining if this imaging technique will enable a predictive metric for therapeutic success. By using a metric such as this, a truly adaptive dose regimen could be offered to patients to tailor the radionuclide dose to each patient's tumour with curative intent and minimise any excess normal tissue toxicity.  

Recent publications

More publications